Original Investigation
Editorial Comment
COVID-19–Specific Strategies for the Treatment of ST-Segment Elevation Myocardial Infarction in China

https://doi.org/10.1016/j.jacc.2020.07.054Get rights and content
Under an Elsevier user license
open archive

Key Words

chest pain center
COVID-19
primary percutaneous coronary intervention
ST-segment elevation myocardial infarction
thrombolysis

Cited by (0)

Dr. Parikh has received institutional research funding from Abbott Vascular, Boston Scientific, Surmodics, Shockwave Medical, and TriReme Medical; has served on the advisory boards of Abbott Vascular, Boston Scientific, Medtronic, Janssen, CSI, and Philips; and has received honoraria from Terumo and Abiomed. Dr. Kirtane has received institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, and ReCor Medical; has received research grants/institutional funding that included fees paid to Columbia University, and/or Cardiovascular Research Foundation for speaking engagements and/or consulting (no speaking/consulting fees were personally received); and has received travel expenses/meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron. Dr. Ranard has reported that she has no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC author instructions page.

Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.